Response to high-dose intravenous immune globulin as a valuable factor predicting the effect of splenectomy in chronic idiopathic thrombocytopenic purpura patients

Chul Won Choi, Byung Soo Kim, Jae Hong Seo, Sang Won Shin, Yeul Hong Kim, Jun Suk Kim, Sang Kyun Sohn, Jae Seok Kim, Dong Gun Shin, Hun Mo Ryoo, Kyung Hee Lee, Je Jung Lee, Ik Joo Chung, Hyeoung Joon Kim, Jae Yong Kwak, Chang Yeol Yim, Jin Seok Ahn, Jung Ae Lee, Young Suk Park

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

This study was conducted to verify whether the response to high-dose intravenous immune globulin (IVIG) was related to the effect of splenectomy in chronic idiopathic thrombocytopenic purpura (ITP) patients. A total of 79 patients over 16 years of age were enrolled in this study. The response to the treatment was classified on the basis of the platelet count as no response (NR, <50 × 109/I), incomplete response (IR, (50-150) × 109/I), and complete response (CR, >150 × 109/I). The response was evaluated after the infusion of high-dose IVIG, within 2 weeks after splenectomy (immediate response), and during a follow-up period of more than 6 months after splenectomy (sustained response), respectively. 58 patients (73.4%) showed responses (CR or IR) to high-dose IVIG. After splenectomy, immediate responses were observed in 73 patients (92%). The response to high-dose IVIG had no relationship with the immediate response to splenectomy (P = 0.333). A follow-up evaluation was possible with 58 patients; 6 patients with NR in immediate responses did not show any response during the follow-up period, and 17 patients relapsed within 6 months after immediate responses, so 35 patients (60.3%) had sustained responses. Responders to IVIG had significantly higher sustained response rates to splenectomy than non-responders (62% vs. 38%, P = 0.001). These results indicate that the response to high-dose IVIG could be a valuable factor predicting the sustained response to splenectomy in chronic ITP patients.

Original languageEnglish
Pages (from-to)197-202
Number of pages6
JournalAmerican Journal of Hematology
Volume66
Issue number3
DOIs
Publication statusPublished - 2001 Mar 3

Fingerprint

Idiopathic Thrombocytopenic Purpura
Intravenous Immunoglobulins
Splenectomy
Platelet Count

Keywords

  • High-dose immune globulin
  • Idiopathic thrombocytopenic purpura (ITP)
  • Splenectomy

ASJC Scopus subject areas

  • Hematology

Cite this

Response to high-dose intravenous immune globulin as a valuable factor predicting the effect of splenectomy in chronic idiopathic thrombocytopenic purpura patients. / Choi, Chul Won; Kim, Byung Soo; Seo, Jae Hong; Shin, Sang Won; Kim, Yeul Hong; Kim, Jun Suk; Sohn, Sang Kyun; Kim, Jae Seok; Shin, Dong Gun; Ryoo, Hun Mo; Lee, Kyung Hee; Lee, Je Jung; Chung, Ik Joo; Kim, Hyeoung Joon; Kwak, Jae Yong; Yim, Chang Yeol; Ahn, Jin Seok; Lee, Jung Ae; Park, Young Suk.

In: American Journal of Hematology, Vol. 66, No. 3, 03.03.2001, p. 197-202.

Research output: Contribution to journalArticle

Choi, Chul Won ; Kim, Byung Soo ; Seo, Jae Hong ; Shin, Sang Won ; Kim, Yeul Hong ; Kim, Jun Suk ; Sohn, Sang Kyun ; Kim, Jae Seok ; Shin, Dong Gun ; Ryoo, Hun Mo ; Lee, Kyung Hee ; Lee, Je Jung ; Chung, Ik Joo ; Kim, Hyeoung Joon ; Kwak, Jae Yong ; Yim, Chang Yeol ; Ahn, Jin Seok ; Lee, Jung Ae ; Park, Young Suk. / Response to high-dose intravenous immune globulin as a valuable factor predicting the effect of splenectomy in chronic idiopathic thrombocytopenic purpura patients. In: American Journal of Hematology. 2001 ; Vol. 66, No. 3. pp. 197-202.
@article{f19dd145d2b0447c900fca1d5ae8f187,
title = "Response to high-dose intravenous immune globulin as a valuable factor predicting the effect of splenectomy in chronic idiopathic thrombocytopenic purpura patients",
abstract = "This study was conducted to verify whether the response to high-dose intravenous immune globulin (IVIG) was related to the effect of splenectomy in chronic idiopathic thrombocytopenic purpura (ITP) patients. A total of 79 patients over 16 years of age were enrolled in this study. The response to the treatment was classified on the basis of the platelet count as no response (NR, <50 × 109/I), incomplete response (IR, (50-150) × 109/I), and complete response (CR, >150 × 109/I). The response was evaluated after the infusion of high-dose IVIG, within 2 weeks after splenectomy (immediate response), and during a follow-up period of more than 6 months after splenectomy (sustained response), respectively. 58 patients (73.4{\%}) showed responses (CR or IR) to high-dose IVIG. After splenectomy, immediate responses were observed in 73 patients (92{\%}). The response to high-dose IVIG had no relationship with the immediate response to splenectomy (P = 0.333). A follow-up evaluation was possible with 58 patients; 6 patients with NR in immediate responses did not show any response during the follow-up period, and 17 patients relapsed within 6 months after immediate responses, so 35 patients (60.3{\%}) had sustained responses. Responders to IVIG had significantly higher sustained response rates to splenectomy than non-responders (62{\%} vs. 38{\%}, P = 0.001). These results indicate that the response to high-dose IVIG could be a valuable factor predicting the sustained response to splenectomy in chronic ITP patients.",
keywords = "High-dose immune globulin, Idiopathic thrombocytopenic purpura (ITP), Splenectomy",
author = "Choi, {Chul Won} and Kim, {Byung Soo} and Seo, {Jae Hong} and Shin, {Sang Won} and Kim, {Yeul Hong} and Kim, {Jun Suk} and Sohn, {Sang Kyun} and Kim, {Jae Seok} and Shin, {Dong Gun} and Ryoo, {Hun Mo} and Lee, {Kyung Hee} and Lee, {Je Jung} and Chung, {Ik Joo} and Kim, {Hyeoung Joon} and Kwak, {Jae Yong} and Yim, {Chang Yeol} and Ahn, {Jin Seok} and Lee, {Jung Ae} and Park, {Young Suk}",
year = "2001",
month = "3",
day = "3",
doi = "10.1002/1096-8652(200103)66:3<197::AID-AJH1044>3.0.CO;2-6",
language = "English",
volume = "66",
pages = "197--202",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Response to high-dose intravenous immune globulin as a valuable factor predicting the effect of splenectomy in chronic idiopathic thrombocytopenic purpura patients

AU - Choi, Chul Won

AU - Kim, Byung Soo

AU - Seo, Jae Hong

AU - Shin, Sang Won

AU - Kim, Yeul Hong

AU - Kim, Jun Suk

AU - Sohn, Sang Kyun

AU - Kim, Jae Seok

AU - Shin, Dong Gun

AU - Ryoo, Hun Mo

AU - Lee, Kyung Hee

AU - Lee, Je Jung

AU - Chung, Ik Joo

AU - Kim, Hyeoung Joon

AU - Kwak, Jae Yong

AU - Yim, Chang Yeol

AU - Ahn, Jin Seok

AU - Lee, Jung Ae

AU - Park, Young Suk

PY - 2001/3/3

Y1 - 2001/3/3

N2 - This study was conducted to verify whether the response to high-dose intravenous immune globulin (IVIG) was related to the effect of splenectomy in chronic idiopathic thrombocytopenic purpura (ITP) patients. A total of 79 patients over 16 years of age were enrolled in this study. The response to the treatment was classified on the basis of the platelet count as no response (NR, <50 × 109/I), incomplete response (IR, (50-150) × 109/I), and complete response (CR, >150 × 109/I). The response was evaluated after the infusion of high-dose IVIG, within 2 weeks after splenectomy (immediate response), and during a follow-up period of more than 6 months after splenectomy (sustained response), respectively. 58 patients (73.4%) showed responses (CR or IR) to high-dose IVIG. After splenectomy, immediate responses were observed in 73 patients (92%). The response to high-dose IVIG had no relationship with the immediate response to splenectomy (P = 0.333). A follow-up evaluation was possible with 58 patients; 6 patients with NR in immediate responses did not show any response during the follow-up period, and 17 patients relapsed within 6 months after immediate responses, so 35 patients (60.3%) had sustained responses. Responders to IVIG had significantly higher sustained response rates to splenectomy than non-responders (62% vs. 38%, P = 0.001). These results indicate that the response to high-dose IVIG could be a valuable factor predicting the sustained response to splenectomy in chronic ITP patients.

AB - This study was conducted to verify whether the response to high-dose intravenous immune globulin (IVIG) was related to the effect of splenectomy in chronic idiopathic thrombocytopenic purpura (ITP) patients. A total of 79 patients over 16 years of age were enrolled in this study. The response to the treatment was classified on the basis of the platelet count as no response (NR, <50 × 109/I), incomplete response (IR, (50-150) × 109/I), and complete response (CR, >150 × 109/I). The response was evaluated after the infusion of high-dose IVIG, within 2 weeks after splenectomy (immediate response), and during a follow-up period of more than 6 months after splenectomy (sustained response), respectively. 58 patients (73.4%) showed responses (CR or IR) to high-dose IVIG. After splenectomy, immediate responses were observed in 73 patients (92%). The response to high-dose IVIG had no relationship with the immediate response to splenectomy (P = 0.333). A follow-up evaluation was possible with 58 patients; 6 patients with NR in immediate responses did not show any response during the follow-up period, and 17 patients relapsed within 6 months after immediate responses, so 35 patients (60.3%) had sustained responses. Responders to IVIG had significantly higher sustained response rates to splenectomy than non-responders (62% vs. 38%, P = 0.001). These results indicate that the response to high-dose IVIG could be a valuable factor predicting the sustained response to splenectomy in chronic ITP patients.

KW - High-dose immune globulin

KW - Idiopathic thrombocytopenic purpura (ITP)

KW - Splenectomy

UR - http://www.scopus.com/inward/record.url?scp=0035110090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035110090&partnerID=8YFLogxK

U2 - 10.1002/1096-8652(200103)66:3<197::AID-AJH1044>3.0.CO;2-6

DO - 10.1002/1096-8652(200103)66:3<197::AID-AJH1044>3.0.CO;2-6

M3 - Article

C2 - 11279626

AN - SCOPUS:0035110090

VL - 66

SP - 197

EP - 202

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 3

ER -